Endocan Financial Statements From 2010 to 2025
| ENDO Stock | USD 0.0001 0.00 0.00% |
Check Endocan Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Endocan Corp's main balance sheet or income statement drivers, such as , as well as many indicators such as . Endocan financial statements analysis is a perfect complement when working with Endocan Corp Valuation or Volatility modules.
Endocan |
Endocan Corp Company Price To Book Analysis
Endocan Corp's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Endocan Corp Price To Book | 18.51 X |
Most of Endocan Corp's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Endocan Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, Endocan Corp has a Price To Book of 18.5052 times. This is 51.93% higher than that of the Basic Materials sector and 178.69% higher than that of the Specialty Chemicals industry. The price to book for all United States stocks is 94.59% lower than that of the firm.
Endocan Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Endocan Corp's current stock value. Our valuation model uses many indicators to compare Endocan Corp value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Endocan Corp competition to find correlations between indicators driving Endocan Corp's intrinsic value. More Info.Endocan Corp is rated as one of the top companies in current valuation category among its peers. It is rated # 5 in shares outstanding category among its peers creating about 36.23 of Shares Outstanding per Current Valuation. Comparative valuation analysis is a catch-all model that can be used if you cannot value Endocan Corp by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Endocan Corp's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Endocan Corp Financial Statements
Endocan Corp investors utilize fundamental indicators, such as revenue or net income, to predict how Endocan Pink Sheet might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Thermic Sciences International develops and sells hemp based products. Thermic Sciences International was incorporated in 1969 and is based in Colorado Springs, Colorado. ENDOCAN CORP operates under Specialty Chemicals classification in the United States and is traded on OTC Exchange.
Other Information on Investing in Endocan Pink Sheet
Endocan Corp financial ratios help investors to determine whether Endocan Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Endocan with respect to the benefits of owning Endocan Corp security.